Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 26 2018 Women and girls of childbearing potential must no longer take valproate medicines...

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

April 23 2018 Buprenorphine has been found to have lower rates of overdose death than methadone...

Class of diabetes drug linked to increased risk of irritable bowel disease

Class of diabetes drug linked to increased risk of irritable bowel disease

March 29 2018 A study has shown that dipeptidylpeptidase-4 inhibitors may increase the risk of...

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

March 29 2018 Mefloquine is safe to use for malaria prevention during pregnancy, a Cochrane...

  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Thursday, 26 April 2018 11:48
  • Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Buprenorphine may be safer than methadone in opioid substitute therapy, study suggests

    Monday, 23 April 2018 16:48
  • Class of diabetes drug linked to increased risk of irritable bowel disease

    Class of diabetes drug linked to increased risk of irritable bowel disease

    Thursday, 29 March 2018 11:27
  • Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Thursday, 29 March 2018 11:21

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageNovember 28 2017

The medicines regulator has issued four Drug Safety Updates relating to gentamicin, quinine, oral tacrolimus preparations, and anti-epileptic drugs.

The MHRA’s gentamicin DSU advises about possible high levels of histamine being present in several different batches of gentamicin injections from different marketing authorisation holders. The manufacturing process of the active pharmaceutical ingredient gentamicin may include higher levels of histamine as a residual from the manufacturing process.

Health professionals are advised to monitor patients for signs of histamine-related adverse effects, including anaphylaxis-type reactions, hypotensive reactions, or increased heart rate. Caution should be used in treating patients with gentamicin, especially if they are also using other drugs which may stimulate histamine release.

The DSU on quinine is a reminder of the dose-dependent effect prolonging the QT-interval in heart rhythm. It says the drug “should be used with caution in patients with risk factors for QT prolongation or in those with atrioventricular block.”

Prescribers need to consider conditions that may impact on QT prolongation such as cardiac disease or electrolyte balance, atrioventricular block or concomitant use of other drugs which can affect the QT interval. Patients requiring phenobarbital or carbamazepine need close monitoring as serum levels could become toxic.

The third DSU advises that changes between oral tacrolimus preparations need to be managed carefully, as “inadvertent switching between tacrolimus products has been associated with reports of toxicity and graft rejection …  tacrolimus has a narrow therapeutic index, and even minor differences in blood levels have the potential to cause graft rejection reactions or toxicity.”

A DSU on oral tacrolimus was first issued in 2012, but the advisory has been reissued as new oral tacrolimus products have been licensed or are now being launched into the market.

The final DSU from relates to considerations about switching between different manufacturers’ anti-epileptic drugs. Advice issued in 2013 still stands, relating to the three risk-based categories of anti-epileptics and changing the brand/manufacturer. Health professionals are now being advised that they should additionally take into account the patient’s perceptions about switching brands.

Links:
MHRA DSU on gentamicin            
MHRA DSU on quinine sulphate                  
MHRA DSU on tacrolimus            
MHRA DSU on anti-epilepsy drugs

Clinical News

May 23 2018 The Court of Appeal has commenced hearing a case around the Government’s cut in pharmacy funding and other changes to community pharmacy introduced in 2016.
May 21 2018  NHS England and Capita’s handling of primary care support services has been criticised in an official report. The National Audit Office has published a review saying that “NHS England and...